Go back

AI use in medicine development ‘needs governance and guidance’

   

Broad use of artificial intelligence brings challenges around transparency and risks of failure, regulators say

The widespread use of artificial intelligence software in medicine development creates “regulatory challenges” that require new guidelines and stronger governance, according to an international group of medicines regulators.

The International Coalition of Medicines Regulatory Authorities issued recommendations around the use of AI in a report, published on 16 August, of a horizon-scanning exercise carried out by several of its members under the leadership of the European Medicines Agency.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.